---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-020728"
form_type: "8-K"
ticker: "PCSA"
cik: "0001533743"
company_name: "Processa Pharmaceuticals, Inc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T00:45:08.196987+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Processa Pharmaceuticals transitions Chief Development Officer to part-time role effective May 1, 2026

## Summary
- Dr. Sian Bigora moves from full-time executive to part-time employee, retains Chief Development and Regulatory Officer title.
- She will no longer be an executive officer under Section 16 of the Exchange Act.
- Existing employment agreement terminated; replaced by new part-time arrangement effective May 1, 2026.
- Dr. Bigora retains all previously granted equity awards and remains eligible for prior bonus compensation.
- Transition is part of her planned path toward retirement, as stated by the company.

## SEC filing metadata
- accession: 0001493152-26-020728
- form_type: 8-K
- ticker: PCSA
- cik: 0001533743
- company_name: Processa Pharmaceuticals, Inc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533743/000149315226020728/0001493152-26-020728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533743/000149315226020728/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-020728
- JSON: https://secwatch.observer/filing/0001493152-26-020728.json
- Plain text: https://secwatch.observer/filing/0001493152-26-020728.txt

## Key facts
- Executive change
  Sian Bigora changed role as Chief Development and Regulatory Officer at Processa Pharmaceuticals, Inc..
  - Action: transitioned from full-time executive officer to part-time employee
  - Role: Chief Development and Regulatory Officer
  source text: On April 30, 2026, Processa Pharmaceuticals, Inc. (the “Company”) approved a transition in the employment status of Dr. Sian Bigora, the Company’s Chief Development and Regulatory Officer, as part of her planned transition toward retirement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1533743/000149315226020728/0001493152-26-020728-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.